All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Catch up with our live social media coverage of real-world studies in AML from the European Hematology Association (EHA) 2024 Hybrid Congress.
June 13—16
Bookmark this article
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up here with our live social media relating to real-world studies in acute myeloid leukemia (AML).
CONGRESS #EHA2024 | Fabio Guolo @UniGenova shares efficacy of CPX-351 in elderly Italian patients with s-AML (N=513).
— AML Hub (@AML_Hub) June 15, 2024
▪️ CR was achieved in 58% pts after induction 1 and 66.3% pts after induction 2.
▪️ CR was significantly higher in pts with NPM1 mutations or ELN 2017 favorable… pic.twitter.com/p8gobTM9Pz
CONGRESS #EHA2024 | Erika Borlenghi, Asst Spedali Civili di Brescia, presents a real-world study evaluating efficacy of venetoclax + hypomethylating agents (VEN-HMA), in comparison with intensive chemotherapy (CT) and HMA alone, in elderly pts with AML (N=406).
— AML Hub (@AML_Hub) June 16, 2024
▪️ Hospitalization… pic.twitter.com/XjTdaHukh5
CONGRESS #EHA2024 | Christian Recher, @CHUdeToulouse, presents real-world outcomes of oral azacitidine maintenance therapy in French pts with AML in remission after frontline treatment (N=81).
— AML Hub (@AML_Hub) June 16, 2024
▪️ mRFS was 23.6 months. RFS rate at 6, 12, and 18 months of treatment initiation were… pic.twitter.com/r3bbwTDadW
CONGRESS | #EHA2024 | Poster
— AML Hub (@AML_Hub) June 18, 2024
Elisabetta Todisco, @asstvalleolona1, presents a real-world study assessing the impact of TP53 mutations on Italian pts with s-AML and t-AML (N=513) receiving CPX-351.
▪️ Compared with wild type (56.6%), CR rate was significantly lower in pts with… pic.twitter.com/rI3LEUBaDQ
CONGRESS | #EHA2024 | Poster
— AML Hub (@AML_Hub) June 17, 2024
Brian Leber @McMasterU presents real-world data from patients with AML who received treatment with oral-Aza maintenance in Canada (N=119).
▪️ Broader population than QUAZAR AML-001 trial (wider age range, more consolidation cycles)
▪️ Survival… pic.twitter.com/fkFeAqSArS
CONGRESS | #EHA2024 | Poster
— AML Hub (@AML_Hub) June 17, 2024
Joana Infante, Centro Hospitalar Universitário de Lisboa Norte, presents real-world data on first-line midostaurin in patients with FLT3m-AML in Portugal (n=76).
▪️ Lower relapse rates in patients who received midostaurin at induction (36.8%),… pic.twitter.com/USnrk1WUcz
CONGRESS #EHA2024 | Sarah Bertoli, @CHUdeToulouse, presents a retrospective study comparing the efficacy of intermediate-dose cytarabine (IDAC) used routinely by the German SAL group (n=474) and the mini consolidations used in the French DATAML registry (n=322) in pts with AML… pic.twitter.com/emyCMN84Mb
— AML Hub (@AML_Hub) June 16, 2024
CONGRESS | #EHA2024 | Poster
— AML Hub (@AML_Hub) June 18, 2024
Rithin Nedumannil @RithinN @Haem_pmcc_rmh presents an analysis showing that time to hematologic recovery is a determinant of CR as a surrogate for OS in patients with AML receiving intensive chemotherapy.
▪️ Poorer OS was observed in patients who… pic.twitter.com/mqv7pKJszM
CONGRESS #EHA2024 | Alberto Hernández Sánchez @alhesan14 @HematoCAUSA shares genomic landscape of adult AML t(8;21)(q22;q22.1) from the HARMONY AML database (N=520) and the prognostic implications. KIT-mu with VAF >25% and male gender with loss of sex chromosome were associated… pic.twitter.com/ttZp16mkJE
— AML Hub (@AML_Hub) June 16, 2024
CONGRESS | #EHA2024 | Poster
— AML Hub (@AML_Hub) June 18, 2024
Christophe Willekens, @GustaveRoussy, presents a retrospective study comparing HMA+VEN for 7 days (“7+7” regime) vs HMA+VEN standard exposure (s-HMA/VEN) in pts with ND AML.
▪️ CRc rate was similar between groups (72%; p=0.955).
▪️ CR rate was 57% vs… pic.twitter.com/419jkD0xeL
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox